Published in Hepatology on April 01, 2003
[Trial of device that is not approved or cleared by the U.S. FDA] | NCT01851252
Statins Reduce the Risk of Cirrhosis and Its Decompensation in Chronic Hepatitis B Patients: A Nationwide Cohort Study. Am J Gastroenterol (2016) 2.80
The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol (2009) 1.69
Treatment of portal hypertension. World J Gastroenterol (2012) 1.39
Invasive and non-invasive diagnosis of cirrhosis and portal hypertension. World J Gastroenterol (2014) 1.20
Current management of the complications of portal hypertension: variceal bleeding and ascites. CMAJ (2006) 1.10
Hepatic venous pressure gradient in cirrhosis: correlation with the size of varices, bleeding, ascites, and child's status. Dig Dis Sci (2006) 1.04
Portal hypertension and gastrointestinal bleeding: diagnosis, prevention and management. World J Gastroenterol (2013) 1.03
In vivo validation of 4D flow MRI for assessing the hemodynamics of portal hypertension. J Magn Reson Imaging (2012) 1.02
Management of varices in patients with cirrhosis. Nat Rev Gastroenterol Hepatol (2013) 0.99
4D flow imaging with MRI. Cardiovasc Diagn Ther (2014) 0.98
Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). Wien Klin Wochenschr (2013) 0.93
Clinical pharmacology of portal hypertension. Gastroenterol Clin North Am (2010) 0.92
Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. Drugs (2015) 0.91
Evolution in the understanding of the pathophysiological basis of portal hypertension: How changes in paradigm are leading to successful new treatments. J Hepatol (2015) 0.90
Hemodynamic effects of the early and long-term administration of propranolol in rats with intrahepatic portal hypertension. Hepatol Int (2008) 0.90
Beta-blockers in liver cirrhosis. Ann Gastroenterol (2014) 0.90
Transjugular intrahepatic portosystemic shunts and portal hypertension-related complications. World J Gastroenterol (2014) 0.88
Cirrhosis and portal hypertension: The importance of risk stratification, the role of hepatic venous pressure gradient measurement. World J Hepatol (2015) 0.88
Non-selective β-blockers improve the correlation of liver stiffness and portal pressure in advanced cirrhosis. J Gastroenterol (2011) 0.86
Sildenafil has no effect on portal pressure but lowers arterial pressure in patients with compensated cirrhosis. Clin Gastroenterol Hepatol (2010) 0.84
Reproducibility study of four-dimensional flow MRI of arterial and portal venous liver hemodynamics: influence of spatio-temporal resolution. Magn Reson Med (2013) 0.83
Use of portal pressure studies in the management of variceal haemorrhage. World J Gastrointest Endosc (2012) 0.83
Benefit of combination β-blocker and endoscopic treatment to prevent variceal rebleeding: a meta-analysis. World J Gastroenterol (2010) 0.83
The management of hospitalized patients with cirrhosis: the Mount Sinai experience and a guide for hospitalists. Dig Dis Sci (2011) 0.82
Gastrointestinal polypoid lesions: a poorly known endoscopic feature of portal hypertension. United European Gastroenterol J (2014) 0.82
After proper optimization of carvedilol dose, do different child classes of liver disease differ in terms of dose tolerance and response on a chronic basis? Saudi J Gastroenterol (2015) 0.81
Endoscopic management of esophageal varices. World J Gastrointest Endosc (2012) 0.81
Transjugular intrahepatic portosystemic shunt in the management of refractory ascites. Semin Intervent Radiol (2005) 0.80
Endoscopic ultrasound guided vascular access and therapy (with videos). Endosc Ultrasound (2015) 0.80
Hepatic venous pressure gradient: worth another look? Dig Dis Sci (2008) 0.80
Impaired regulation of portal venous flow in response to a meal challenge as quantified by 4D flow MRI. J Magn Reson Imaging (2015) 0.79
Natural history of major complications in hepatitis C virus-related cirrhosis evaluated by per-rectal portal scintigraphy. World J Gastroenterol (2005) 0.78
Primary prevention of variceal bleeding: pharmacological therapy versus endoscopic banding. N Am J Med Sci (2013) 0.78
Prevention and management of variceal hemorrhage. Int J Hepatol (2013) 0.78
Prevention and management of gastroesophageal varices in cirrhosis. Int J Hepatol (2012) 0.78
Recent advances in the management of variceal bleeding. Gastroenterol Rep (Oxf) (2017) 0.76
Portal hypertension in patients with cirrhosis: indirect assessment of hepatic venous pressure gradient by measuring azygos flow with 2D-cine phase-contrast magnetic resonance imaging. Eur Radiol (2015) 0.76
Is it time to replace propranolol with carvedilol for portal hypertension? World J Gastrointest Endosc (2015) 0.76
Carvedilol for portal hypertension in cirrhosis: systematic review with meta-analysis. BMJ Open (2016) 0.76
Effects of Sapropterin on Portal and Systemic Hemodynamics in Patients With Cirrhosis and Portal Hypertension: A Bicentric Double-Blind Placebo-Controlled Study. Am J Gastroenterol (2015) 0.76
Is there any vindication for low dose nonselective β-blocker medication in patients with liver cirrhosis? Clin Mol Hepatol (2012) 0.76
MDCT, MR and interventional radiology in biliary atresia candidates for liver transplantation. World J Radiol (2011) 0.76
Blood Microbiome Quantity and the Hyperdynamic Circulation in Decompensated Cirrhotic Patients. PLoS One (2017) 0.75
Gastrointestinal Bleeding in Cirrhotic Patients with Portal Hypertension. ISRN Hepatol (2013) 0.75
Carvedilol-NSBB of choice in all cirrhotics? Short title: Carvedilol for portal hypertension. Saudi J Gastroenterol (2015) 0.75
Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension. World J Hepatol (2017) 0.75
Arterial blood pressure is closely related to ascites development in compensated HCV-related cirrhosis. PLoS One (2014) 0.75
Application of a standardised protocol for hepatic venous pressure gradient measurement improves quality of readings and facilitates reduction of variceal bleeding in cirrhotics. Singapore Med J (2016) 0.75
Rethinking the role of non-selective beta blockers in patients with cirrhosis and portal hypertension. World J Hepatol (2016) 0.75
Non-selective β-blockers in advanced cirrhosis: a critical review of the effects on overall survival and renal function. BMJ Open Gastroenterol (2016) 0.75
Hemodynamic effects of propranolol with spironolactone in patients with variceal bleeds: a randomized controlled trial. World J Gastroenterol (2008) 0.75
Research progress in hepatic encephalopathy in recent 10 years: A Web of Science-based literature analysis. Neural Regen Res (2012) 0.75
Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis. World J Gastroenterol (2016) 0.75
Use of non-selective beta blockers in cirrhosis: the evidence we need before closing (or not) the window. World J Gastroenterol (2015) 0.75
Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med (2010) 8.40
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med (2005) 6.31
Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med (2010) 5.37
Management of cirrhosis and ascites. N Engl J Med (2004) 4.31
Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology (2007) 4.09
Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology (2012) 3.86
Portal hypertension and the outcome of surgery for hepatocellular carcinoma in compensated cirrhosis: a systematic review and meta-analysis. Hepatology (2015) 3.63
Role of a research ethics committee in follow-up and publication of results. Lancet (2003) 3.61
Transjugular intrahepatic portosystemic shunting versus paracentesis plus albumin for refractory ascites in cirrhosis. Gastroenterology (2002) 3.50
Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. Hepatology (2013) 3.31
Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology (2002) 2.93
Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study. Gastroenterology (2008) 2.89
Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology (2002) 2.86
Multiple emergences of genetically diverse amphibian-infecting chytrids include a globalized hypervirulent recombinant lineage. Proc Natl Acad Sci U S A (2011) 2.78
Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology (2006) 2.39
Bacterial DNA translocation is associated with systemic circulatory abnormalities and intrahepatic endothelial dysfunction in patients with cirrhosis. Hepatology (2010) 2.39
Emergency sclerotherapy versus vasoactive drugs for variceal bleeding in cirrhosis: a Cochrane meta-analysis. Gastroenterology (2003) 2.38
EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). J Hepatol (2003) 2.37
Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation. J Hepatol (2003) 2.35
Influence of hepatitis B virus genotype on the long-term outcome of chronic hepatitis B in western patients. Gastroenterology (2002) 2.34
Beneficial effects of sorafenib on splanchnic, intrahepatic, and portocollateral circulations in portal hypertensive and cirrhotic rats. Hepatology (2009) 2.33
Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol (2009) 2.22
TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. Hepatology (2002) 2.12
Risk factors for intraductal papillary mucinous neoplasm (IPMN) of the pancreas: a multicentre case-control study. Am J Gastroenterol (2013) 2.11
Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study. Gastroenterology (2007) 2.07
Hepatic venous pressure gradient identifies patients at risk of severe hepatitis C recurrence after liver transplantation. Hepatology (2006) 2.03
[A secure job for ever]. Med Clin (Barc) (2003) 2.01
Activated human hepatic stellate cells express the renin-angiotensin system and synthesize angiotensin II. Gastroenterology (2003) 2.01
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology (2006) 1.96
Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol (2003) 1.90
Pharmacological reduction of portal pressure and long-term risk of first variceal bleeding in patients with cirrhosis. Am J Gastroenterol (2006) 1.90
Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. Hepatology (2007) 1.88
Inhibition of VEGF receptor-2 decreases the development of hyperdynamic splanchnic circulation and portal-systemic collateral vessels in portal hypertensive rats. J Hepatol (2005) 1.87
Short- and long-term effects of the transjugular intrahepatic portosystemic shunt on portal vein thrombosis in patients with cirrhosis. Gut (2011) 1.87
Hepatorenal syndrome. Lancet (2003) 1.86
An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl (2007) 1.83
Effects of treatment of hepatorenal syndrome before transplantation on posttransplantation outcome. A case-control study. J Hepatol (2004) 1.82
Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology (2009) 1.76
Improved clinical outcome using polytetrafluoroethylene-coated stents for TIPS: results of a randomized study. Gastroenterology (2004) 1.71
Fully covered, self-expandable metal stents for first-step endoscopic treatment of biliary leaks secondary to hepato-biliary surgery: a retrospective study. Dig Liver Dis (2012) 1.71
How to prevent varices from bleeding: shades of grey--the case for nonselective beta blockers. Gastroenterology (2007) 1.70
Von Willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut (2011) 1.66
Obesity is an independent risk factor for clinical decompensation in patients with cirrhosis. Hepatology (2011) 1.63
Mitigating amphibian disease: strategies to maintain wild populations and control chytridiomycosis. Front Zool (2011) 1.62
Effects of splenic artery occlusion on portal pressure in patients with cirrhosis and portal hypertension. Liver Transpl (2006) 1.60
Hepatic venous pressure gradient and prognosis in patients with acute variceal bleeding treated with pharmacologic and endoscopic therapy. J Hepatol (2007) 1.60
Type-1 hepatorenal syndrome associated with infections in cirrhosis: natural history, outcome of kidney function, and survival. Hepatology (2014) 1.60
Factors driving pathogenicity vs. prevalence of amphibian panzootic chytridiomycosis in Iberia. Ecol Lett (2010) 1.60
MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology (2005) 1.58
Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (2003) 1.57
Ultrasonographic evaluation of liver surface and transient elastography in clinically doubtful cirrhosis. J Hepatol (2010) 1.53
Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study. Hepatology (2010) 1.53
Presence of bacterial-DNA in cirrhosis identifies a subgroup of patients with marked inflammatory response not related to endotoxin. J Hepatol (2007) 1.51
Portal hypertension and its complications. Gastroenterology (2008) 1.50
Docosahexaenoic acid (DHA) blunts liver injury by conversion to protective lipid mediators: protectin D1 and 17S-hydroxy-DHA. FASEB J (2006) 1.50
Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology (2009) 1.49
Proteomic and phenotypic profiling of the amphibian pathogen Batrachochytrium dendrobatidis shows that genotype is linked to virulence. Mol Ecol (2009) 1.49
Portal hypertension in children: expert pediatric opinion on the report of the Baveno v Consensus Workshop on Methodology of Diagnosis and Therapy in Portal Hypertension. Pediatr Transplant (2012) 1.49
The transcription factor KLF2 mediates hepatic endothelial protection and paracrine endothelial-stellate cell deactivation induced by statins. J Hepatol (2012) 1.48
[Organization and functioning model of biomedical research structures. Situation and future challenges]. Med Clin (Barc) (2008) 1.46
The management of portal hypertension: rational basis, available treatments and future options. J Hepatol (2008) 1.43
Chytrid fungus in Europe. Emerg Infect Dis (2005) 1.43
Disruption of negative feedback loop between vasohibin-1 and vascular endothelial growth factor decreases portal pressure, angiogenesis, and fibrosis in cirrhotic rats. Hepatology (2014) 1.43
Use of noninvasive markers of portal hypertension and timing of screening endoscopy for gastroesophageal varices in patients with chronic liver disease. Hepatology (2013) 1.43
Non invasive evaluation of portal hypertension using transient elastography. J Hepatol (2011) 1.42
Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. Hepatology (2006) 1.42
Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity. Gastroenterology (2006) 1.41
Anticoagulation in cirrhosis: ready … set … wait! Hepatology (2013) 1.41
Developments and controversies in the management of oesophageal and gastric varices. Gut (2010) 1.40
Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver diseases and European Association for the study of the liver single-topic conference. Hepatology (2008) 1.40
A specialized, nurse-run titration clinic: a feasible option for optimizing beta-blockade in non-clinical trial patients. Am J Gastroenterol (2010) 1.38
[Deaths by a medical resident. Could they have been avoided?]. Med Clin (Barc) (2003) 1.38
Invasive pathogens threaten species recovery programs. Curr Biol (2008) 1.37
Endogenous cannabinoids: a new system involved in the homeostasis of arterial pressure in experimental cirrhosis in the rat. Gastroenterology (2002) 1.35
Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology (2005) 1.35
Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology (2002) 1.30
Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology (2004) 1.30
Prognostic importance of the cause of renal failure in patients with cirrhosis. Gastroenterology (2010) 1.29
Effect of intravenous albumin on systemic and hepatic hemodynamics and vasoactive neurohormonal systems in patients with cirrhosis and spontaneous bacterial peritonitis. J Hepatol (2004) 1.28
Endoscopic ultrasound-guided drainage of pancreatic fluid collections. World J Gastrointest Endosc (2012) 1.25
Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol (2012) 1.23
Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet-derived growth factor blockade in rats. Hepatology (2007) 1.23
Platelet count is not a predictor of the presence or development of gastroesophageal varices in cirrhosis. Hepatology (2008) 1.21
Endoscopic band ligation in the treatment of portal hypertension. Nat Clin Pract Gastroenterol Hepatol (2005) 1.20